Literature DB >> 2847170

Oligomeric structure of a prototype retrovirus glycoprotein.

D Einfeld1, E Hunter.   

Abstract

The structure of the Rous sarcoma virus envelope glycoprotein complex was studied by sedimentation gradient centrifugation analyses of detergent-solubilized wild-type and mutant envelope (env) gene products. These studies show that the envelope glycoprotein forms an oligomer during biosynthesis, which is most likely a trimer, and that this is the form of the complex found in virions. Our results are consistent with oligomer formation and transport out of the endoplasmic reticulum being closely linked. From analyses of mutant envelope proteins we conclude that the extracellular domain of the glycoprotein is sufficient for oligomer formation but that the transmembrane domain is required to stabilize this complex. Additional experiments suggest that interactions between external domains of the membrane-spanning, gp37 polypeptides are those most important for the formation of trimers. The significance of these observations to retroviral replication and implications for antiviral drug development are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847170      PMCID: PMC282525          DOI: 10.1073/pnas.85.22.8688

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The structure of the Rous sarcoma virus glycoprotein complex.

Authors:  G Pauli; W Rohde; E Harms
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Biological techniques for avian sarcoma viruses.

Authors:  E Hunter
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Evidence from studies with a cross-linking reagent that the haemagglutinin of influenza virus is a trimer.

Authors:  D C Wiley; J J Skehel; M Waterfield
Journal:  Virology       Date:  1977-06-15       Impact factor: 3.616

4.  Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope.

Authors:  D P Bolognesi; H Bauer; H Gelderblom; G Hüper
Journal:  Virology       Date:  1972-03       Impact factor: 3.616

5.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.

Authors:  I A Wilson; J J Skehel; D C Wiley
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

6.  Restriction endonuclease and nucleotide sequence analyses of molecularly cloned unintegrated avian tumor virus DNA: structure of large terminal repeats in circle junctions.

Authors:  R A Katz; C A Omer; J H Weis; S A Mitsialis; A J Faras; R V Guntaka
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

7.  Chemical crosslinking of proteins in avian sarcoma and leukemia viruses.

Authors:  R B Pepinsky; D Cappiello; C Wilkowski; V M Vogt
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

8.  Infectious cell entry mechanism of influenza virus.

Authors:  A Yoshimura; K Kuroda; K Kawasaki; S Yamashina; T Maeda; S Ohnishi
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  Role for adenosine triphosphate in regulating the assembly and transport of vesicular stomatitis virus G protein trimers.

Authors:  R W Doms; D S Keller; A Helenius; W E Balch
Journal:  J Cell Biol       Date:  1987-11       Impact factor: 10.539

10.  Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses.

Authors:  J White; K Matlin; A Helenius
Journal:  J Cell Biol       Date:  1981-06       Impact factor: 10.539

View more
  71 in total

1.  Soluble receptor-induced retroviral infection of receptor-deficient cells.

Authors:  R Damico; P Bates
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.

Authors:  Daniel J Knauss; John A T Young
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Kinetic analysis of binding interaction between the subgroup A Rous sarcoma virus glycoprotein SU and its cognate receptor Tva: calcium is not required for ligand binding.

Authors:  Xuemei Yu; Qing-Yin Wang; Ying Guo; Klavs Dolmer; John A T Young; Peter G W Gettins; Lijun Rong
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus.

Authors:  P J Gallagher; J M Henneberry; J F Sambrook; M J Gething
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses.

Authors:  J L Battini; J M Heard; O Danos
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles.

Authors:  C D Weiss; J A Levy; J M White
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

8.  A myristylated form of the sea oncoprotein can transform chicken embryo fibroblasts.

Authors:  A J Crowe; M J Hayman
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.

Authors:  C Wild; J W Dubay; T Greenwell; T Baird; T G Oas; C McDanal; E Hunter; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.

Authors:  G Courtois; L Bénit; Y Mikaeloff; M Pauchard; M Charon; P Varlet; S Gisselbrecht
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.